ZIOPHARM Oncology Inc
Most Recent
HealthcareWill Genocea Stock Bounce Back? In-Depth Analysis
Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Company & Industry OverviewsCell Therapy Market Could Boost Celgene’s Long-Term Growth
With the acquisition of Juno Therapeutics, Celgene will benefit from all of Juno Therapeutics’ facilities related to cell therapy.
Company & Industry OverviewsBehind Celgene’s Strategy in the Juno Therapeutics Acquisition
With the acquisition of Juno Therapeutics (JUNO), Celgene (CELG) will likely become an established cellular immunotherapy company.
Company & Industry OverviewsHow Did Ziopharm Keep XBI from Losing More Ground?
Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.
Company & Industry OverviewsArena Rose 14% in XBI’s Small-Cap Space
Arena Pharmaceuticals (ARNA) rose 14% on November 2, 2015. The stock went up on high trading volumes with ~4.7 million shares being traded.